Janssen, Mitsubishi face lawsuits over kidney injuries from diabetes drug Invokana

by Eric Pearson

Janssen Pharmaceuticals and Mitsubishi Tanabe Pharma are facing dozens of lawsuits filed by patients who suffered kidney damage or other complications linked to the diabetes drug Invokana. Attorneys representing patients who were injured after using Invokana recently filed a motion to consolidate lawsuits filed in federal and state courts against Janssen and Mitsubishi in a federal multidistrict litigation (MDL).

Invokana (canagliflozin) was approved by the Food and Drug Administration in March 2013. The drug is part of a class of prescription medications known as sodium-glucose cotransporter-2 (SGLT2) inhibitors. These drugs lower blood sugar levels in patients with type 2 diabetes by helping the kidneys remove sugar from the body through a patient’s urine.

In June 2016, the FDA strengthened existing warnings about the risk of kidney injury for patients taking Invokana or other SGLT2 inhibitors. The agency warned that patients taking Invokana or similar drugs may develop kidney injuries that can cause blood sugar to build up in the body. If left untreated, patients who experience complications from Invokana may develop severe kidney damage or diabetic ketoacidosis, a condition caused by the buildup of acid in the blood.

The FDA reports that it has received more than 100 reports of patients who suffered kidney damage after using Invokana or other SGLT2 inhibitors. The agency says that the majority of these cases occurred within one month of the patient beginning treatment with the drug.

Janssen and Mitsubishi are facing at least 87 lawsuits in Pennsylvania state court from patients who suffered kidney injury or other complications from Invokana. The drugmakers are also facing at least 56 lawsuits filed in California, Georgia, Illinois, New Jersey, and New York federal courts from patients who suffered complications from Invokana.

Lawyers representing the federal and state Invokana plaintiffs recently filed a motion asking for the dozens of lawsuits against Janssen and Mitsubishi to be consolidated in an MDL in New Jersey federal district court. The attorneys stated in their motion that they expected the number of Invokana plaintiffs to increase significantly as the litigation against the two pharmaceutical companies progresses.

Victims of Dangerous Drugs and Medical Products Have Legal Rights

Patients who have been seriously injured as a result of complications from dangerous prescription drugs or other pharmaceutical products may be eligible to file a lawsuit against the manufacturer. The first step in taking legal action is to speak with an attorney regarding your legal rights to learn more about whether you may qualify to file a case.

The lawyers at Heygood, Orr & Pearson have filed hundreds lawsuits on behalf of individuals who were hurt by dangerous drugs, defective medical devices, or other dangerous products. Our law firm believes that that when products sold by pharmaceutical companies cause serious or fatal injuries, they should be held responsible for the harm caused by their products in a court of law.

The attorneys at Heygood, Orr & Pearson have tried hundreds of cases to verdict and achieved settlements on behalf of our clients in hundreds more. Our law firm has collected more than $200 million in verdicts and settlements over the last several years in cases relating to defective pharmaceutical products and other legal matters.

For a free legal consultation about your case and to learn more about whether you may qualify to file a lawsuit, contact the lawyers at Heygood, Orr & Pearson. You can reach us by calling toll-free at 1-877-446-9001, or by following the link to our free case evaluation form and answering a few brief questions about your case to get started.

by Eric Pearson

Eric Pearson is a licensed attorney and a partner at HO&P who handles commercial and personal injury lawsuits. Eric has been selected to the Super Lawyers List, a Thomson Reuters publication.